Skip to content

Unlocking the Potential and Risks of Psychedelic Drugs

In Simple Terms

In the U.S., more people are using psychedelic drugs to help with mental health issues. While these drugs can be promising, they also come with risks like long-term vision problems. Universities like Johns Hopkins are opening clinics to study and treat these rare side effects and support patients.

Growing Popularity and Risks

Psychedelic drugs are gaining popularity in the United States, with several states legalizing their use and the federal government expanding research into their potential for treating mental health conditions. Drugs like psilocybin and MDMA show promise in treating PTSD and treatment-resistant depression. However, they are not without risks, as they can trigger manic episodes and bipolar disorders, even in people with no prior history of such conditions.

Specialized Clinics: A Step Toward Treatment

In 2022, Johns Hopkins University opened the first U.S. clinic dedicated to studying and treating the long-term side effects of psychedelic drugs. This clinic addresses the urgent need to understand and manage the rare symptoms that can arise from using these substances. This initiative is crucial for tackling serious conditions that remain poorly understood.

Visual Disturbances and Psychological Effects

One of the rare symptoms caused by psychedelic drugs is Hallucinogen Persisting Perception Disorder (HPPD), which manifests as visual issues like seeing visual snow or halos around objects. This disorder can last for a long time, sometimes years, prompting many patients to seek specialized medical help. The clinics offer treatment using a combination of antidepressants and sedatives, achieving a good rate of full recovery within a year.

Challenges and Ongoing Research

Scientists are still in the early stages of understanding the prevalence of long-term problems associated with psychedelic drugs. Part of the knowledge gap is due to the primary use of these drugs for non-medical purposes, leading to underreporting of adverse effects. However, some studies suggest that up to 4.2% of psychedelic drug users experience HPPD.

Conclusion

Specialized clinics for addressing the effects of psychedelic drugs are an important step toward understanding and treating the rare and serious symptoms these substances can cause. As their use for medical purposes grows, ongoing research and the development of effective treatment strategies remain essential to ensure user safety. These continuous efforts contribute to providing appropriate care and hope for many suffering from long-term side effects.